| License: Creative Commons Attribution 4.0 PDF - Published Version (3MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-458906
- DOI to cite this document:
- 10.5283/epub.45890
Winter, Julia 
; Meyer, Magdalena ; Berger, Ilona ; Royer, Melanie ; Bianchi, Marta ; Kuffner, Kerstin ; Peters, Sebastian ; Stang, Simone ; Langgartner, Dominik ; Hartmann, Finn ; Schmidtner, Anna K. ; Reber, Stefan O. ; Bosch, Oliver J. ; Bludau, Anna ; Slattery, David A. ; van den Burg, Erwin H. ; Jurek, Benjamin ; Neumann, Inga D.
; Meyer, Magdalena ; Berger, Ilona ; Royer, Melanie ; Bianchi, Marta ; Kuffner, Kerstin ; Peters, Sebastian ; Stang, Simone ; Langgartner, Dominik ; Hartmann, Finn ; Schmidtner, Anna K. ; Reber, Stefan O. ; Bosch, Oliver J. ; Bludau, Anna ; Slattery, David A. ; van den Burg, Erwin H. ; Jurek, Benjamin ; Neumann, Inga D. Abstract
The neuropeptide oxytocin (OXT) has generated considerable interest as potential treatment for psychiatric disorders, including anxiety and autism spectrum disorders. However, the behavioral and molecular consequences associated with chronic OXT treatment and chronic receptor (OXTR) activation have scarcely been studied, despite the potential therapeutic long-term use of intranasal OXT. Here, we ...
Owner only: item control page
Download Statistics